vs

Side-by-side financial comparison of AUTONATION, INC. (AN) and Becton Dickinson (BDX). Click either name above to swap in a different company.

AUTONATION, INC. is the larger business by last-quarter revenue ($6.9B vs $5.3B, roughly 1.3× Becton Dickinson). Becton Dickinson runs the higher net margin — 7.3% vs 2.5%, a 4.8% gap on every dollar of revenue. On growth, Becton Dickinson posted the faster year-over-year revenue change (-0.4% vs -3.9%). Becton Dickinson produced more free cash flow last quarter ($549.0M vs $64.2M). Over the past eight quarters, AUTONATION, INC.'s revenue compounded faster (3.4% CAGR vs 2.0%).

AutoNation, Inc. is an American automotive retailer based in Fort Lauderdale, Florida, which provides new and pre-owned vehicles and associated services in the United States. The company was founded by Wayne Huizenga in 1996, starting with twelve AutoNation locations, and now has more than 300 retail outlets.

Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.

AN vs BDX — Head-to-Head

Bigger by revenue
AN
AN
1.3× larger
AN
$6.9B
$5.3B
BDX
Growing faster (revenue YoY)
BDX
BDX
+3.6% gap
BDX
-0.4%
-3.9%
AN
Higher net margin
BDX
BDX
4.8% more per $
BDX
7.3%
2.5%
AN
More free cash flow
BDX
BDX
$484.8M more FCF
BDX
$549.0M
$64.2M
AN
Faster 2-yr revenue CAGR
AN
AN
Annualised
AN
3.4%
2.0%
BDX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AN
AN
BDX
BDX
Revenue
$6.9B
$5.3B
Net Profit
$172.1M
$382.0M
Gross Margin
17.5%
45.9%
Operating Margin
4.5%
10.5%
Net Margin
2.5%
7.3%
Revenue YoY
-3.9%
-0.4%
Net Profit YoY
-7.5%
24.0%
EPS (diluted)
$4.68
$1.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AN
AN
BDX
BDX
Q4 25
$6.9B
$5.3B
Q3 25
$7.0B
$5.9B
Q2 25
$7.0B
$5.5B
Q1 25
$6.7B
$5.3B
Q4 24
$7.2B
$5.2B
Q3 24
$6.6B
$5.4B
Q2 24
$6.5B
$5.0B
Q1 24
$6.5B
$5.0B
Net Profit
AN
AN
BDX
BDX
Q4 25
$172.1M
$382.0M
Q3 25
$215.1M
$493.0M
Q2 25
$86.4M
$574.0M
Q1 25
$175.5M
$308.0M
Q4 24
$186.1M
$303.0M
Q3 24
$185.8M
$400.0M
Q2 24
$130.2M
$487.0M
Q1 24
$190.1M
$537.0M
Gross Margin
AN
AN
BDX
BDX
Q4 25
17.5%
45.9%
Q3 25
17.6%
47.5%
Q2 25
18.3%
47.8%
Q1 25
18.2%
42.8%
Q4 24
17.2%
43.2%
Q3 24
18.0%
45.7%
Q2 24
17.9%
46.2%
Q1 24
18.5%
45.7%
Operating Margin
AN
AN
BDX
BDX
Q4 25
4.5%
10.5%
Q3 25
5.3%
11.8%
Q2 25
3.1%
16.0%
Q1 25
5.0%
10.4%
Q4 24
4.7%
8.8%
Q3 24
5.3%
11.4%
Q2 24
4.2%
12.1%
Q1 24
5.2%
14.5%
Net Margin
AN
AN
BDX
BDX
Q4 25
2.5%
7.3%
Q3 25
3.1%
8.4%
Q2 25
1.2%
10.4%
Q1 25
2.6%
5.8%
Q4 24
2.6%
5.9%
Q3 24
2.8%
7.4%
Q2 24
2.0%
9.8%
Q1 24
2.9%
10.6%
EPS (diluted)
AN
AN
BDX
BDX
Q4 25
$4.68
$1.34
Q3 25
$5.65
$1.71
Q2 25
$2.26
$2.00
Q1 25
$4.45
$1.07
Q4 24
$4.62
$1.04
Q3 24
$4.61
$1.37
Q2 24
$3.20
$1.68
Q1 24
$4.49
$1.85

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AN
AN
BDX
BDX
Cash + ST InvestmentsLiquidity on hand
$58.6M
$740.0M
Total DebtLower is stronger
$3.7B
Stockholders' EquityBook value
$2.3B
$25.3B
Total Assets
$14.4B
$54.8B
Debt / EquityLower = less leverage
1.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AN
AN
BDX
BDX
Q4 25
$58.6M
$740.0M
Q3 25
$97.6M
$641.0M
Q2 25
$62.9M
$735.0M
Q1 25
$70.5M
$667.0M
Q4 24
$59.8M
$711.0M
Q3 24
$60.2M
$1.7B
Q2 24
$85.9M
$4.5B
Q1 24
$60.3M
$2.3B
Total Debt
AN
AN
BDX
BDX
Q4 25
$3.7B
Q3 25
Q2 25
Q1 25
$3.1B
Q4 24
$2.6B
Q3 24
$3.1B
Q2 24
$3.1B
Q1 24
$3.1B
Stockholders' Equity
AN
AN
BDX
BDX
Q4 25
$2.3B
$25.3B
Q3 25
$2.5B
$25.4B
Q2 25
$2.5B
$25.5B
Q1 25
$2.4B
$25.2B
Q4 24
$2.5B
$25.2B
Q3 24
$2.4B
$25.9B
Q2 24
$2.2B
$25.9B
Q1 24
$2.4B
$25.6B
Total Assets
AN
AN
BDX
BDX
Q4 25
$14.4B
$54.8B
Q3 25
$14.2B
$55.3B
Q2 25
$13.6B
$54.9B
Q1 25
$13.3B
$54.5B
Q4 24
$13.0B
$54.7B
Q3 24
$12.9B
$57.3B
Q2 24
$12.8B
$55.6B
Q1 24
$12.0B
$54.2B
Debt / Equity
AN
AN
BDX
BDX
Q4 25
1.58×
Q3 25
Q2 25
Q1 25
1.29×
Q4 24
1.06×
Q3 24
1.32×
Q2 24
1.43×
Q1 24
1.32×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AN
AN
BDX
BDX
Operating Cash FlowLast quarter
$150.5M
$657.0M
Free Cash FlowOCF − Capex
$64.2M
$549.0M
FCF MarginFCF / Revenue
0.9%
10.5%
Capex IntensityCapex / Revenue
1.2%
2.1%
Cash ConversionOCF / Net Profit
0.87×
1.72×
TTM Free Cash FlowTrailing 4 quarters
$-197.5M
$2.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AN
AN
BDX
BDX
Q4 25
$150.5M
$657.0M
Q3 25
$191.7M
$1.4B
Q2 25
$-177.8M
$1.2B
Q1 25
$-52.5M
$164.0M
Q4 24
$149.8M
$693.0M
Q3 24
$-70.0M
$1.2B
Q2 24
$-59.6M
$1.3B
Q1 24
$294.5M
$514.0M
Free Cash Flow
AN
AN
BDX
BDX
Q4 25
$64.2M
$549.0M
Q3 25
$122.8M
$1.0B
Q2 25
$-256.8M
$1.0B
Q1 25
$-127.7M
$35.0M
Q4 24
$83.5M
$588.0M
Q3 24
$-151.0M
$882.0M
Q2 24
$-147.1M
$1.1B
Q1 24
$200.8M
$380.0M
FCF Margin
AN
AN
BDX
BDX
Q4 25
0.9%
10.5%
Q3 25
1.7%
17.0%
Q2 25
-3.7%
19.0%
Q1 25
-1.9%
0.7%
Q4 24
1.2%
11.4%
Q3 24
-2.3%
16.2%
Q2 24
-2.3%
22.4%
Q1 24
3.1%
7.5%
Capex Intensity
AN
AN
BDX
BDX
Q4 25
1.2%
2.1%
Q3 25
1.0%
6.0%
Q2 25
1.1%
3.2%
Q1 25
1.1%
2.4%
Q4 24
0.9%
2.0%
Q3 24
1.2%
5.4%
Q2 24
1.4%
3.6%
Q1 24
1.4%
2.7%
Cash Conversion
AN
AN
BDX
BDX
Q4 25
0.87×
1.72×
Q3 25
0.89×
2.75×
Q2 25
-2.06×
2.12×
Q1 25
-0.30×
0.53×
Q4 24
0.80×
2.29×
Q3 24
-0.38×
2.94×
Q2 24
-0.46×
2.66×
Q1 24
1.55×
0.96×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AN
AN

New Vehicle$3.4B50%
Transferred At Point In Time$1.7B24%
Parts And Service$1.2B18%
Finance And Insurance Net$369.4M5%
Transferred Over Time$221.4M3%
Other$3.5M0%

BDX
BDX

Other$2.8B53%
Medication Management Solutions$678.0M13%
Urologyand Critical Care$339.0M6%
Surgery$310.0M6%
Peripheral Intervention$265.0M5%
Specimen Management$245.0M5%
Advanced Patient Monitoring$178.0M3%
Diagnostic Solutions$176.0M3%
Bio Pharma Systems$150.0M3%
Biosciences$124.0M2%

Related Comparisons